Niosomes are vesicles composed of non-ionic surfactants, which are biodegradable, comparatively nontoxic, more stable and cheap, an alternative to liposomes. They existing a structure similar to liposome and hence they can represent alternative vesicular systems with respect to liposomes. The niosome ability to encapsulate different type of drugs within their multi environmental structure. These review article emphases on the structure of niosome, advantages of niosomes, methods of preparation, characterization of niosomes, application of niosomes.
Introduction
Niosomes are a novel drug delivery system, in which the drug is encapsulated in a vesicle. The vesicle is composed of a bilayer of nonionic surface active agents and hence the name niosomes. The niosomes are extremely small, and microscopic in size. Their size lies in the nanometric scale. Although structurally similar to liposomes, they offer several advantages over them. Niosomes have recently been shown to greatly increase transdermal drug delivery and also can be used in targeted drug delivery, and thus increased study in these structures can provide new methods for drug delivery. 3 Niosomes can entrap solutes in manner equivalent to liposomes. Niosomes are osmotically active and stable. Niosomes exhibit flexibility in their structural characteristics. Niosomes can improve the performance of drug molecules. Better availability to particular site just by protecting drug from biological environment.
Salient features of niosomes
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vmetkari@yahoo.com (V.B.Metkari) 2230-7842 / © 2014 JCPR. All rights reserved. 1, 2 They improve therapeutics efficiency of drug molecules by delayed clearance from the circulation, protecting the drug from biological environment and restricting effects to target cells. The vesicle suspension is waterbased vehicle. This gives high patient compliance in comparison with oily dosage forms. The vesicles may act as a depot, releasing the drug in a controlled way. They can reduce drug toxicity because of their non-ionic nature. They have an infrastructure consisting of hydrophilic, amphiphilic and lipophilic moieties together and as a result can accommodate drug molecules with a wide range of solubilities. Structurally, niosomes are analogous to liposomes, in that they are also made up of a bilayer. However, the bilayer in the case of niosomes is made up of non-ionic surface active agents rather than phospholipids as seen in the case of liposomes. Most surface active agents when immersed in water yield micellar structures however some surfactants can yield bilayer vesicles which are niosomes. Niosomes may be unilamellar or multilamellar depending on the method used to prepare them. The niosome is prepared of a surfactant bilayer with its hydrophilic ends exposed on the outside and inside of the vesicle, while the hydrophobic chains face each other within the bilayer. Hence, the vesicle holds hydrophilic drugs within the space enclosed in the vesicle, while hydrophobic drugs are embedded within the bilayer itself. The figure above will give a better idea of what a niosome looks like and where the drug is located within the vesicle. 6 This method involves slowly introducing a solution of surfactant dissolved in diethyl ether into warm water maintained at 60°C. The surfactant mixture in ether is injected through 14-gauge needle into an aqueous solution of material. Vaporization of ether leads to formation of single layered vesicles. Depending upon the conditions used the diameter of the vesicle range from 50 to 1000 nm. 2.2 Hand shaking (film) method 7 The mixture of surfactant and cholesterol are dissolved in a volatile organic solvent (diethyl ether, chloroform or methanol) in a round bottom flask these two are vesicle forming agents. Then organic solvent is removed at room temperature (20°C) using rotary evaporator leaving a thin layer of solid mixture deposited on the wall of the flask. The dried surfactant film can be rehydrated with aqueous phase at 0-60°C with gentle agitation. This process forms typical multilamellar niosomes. Finally Sonicate the niosomes obtained and it should be kept in overnight. Large multilamellar vesicles are prepared. 8 The new thing in this method is the removal of solvent from an emulsion by evaporation. The surfactant and cholesterol are dissolved in ether or chloroform or in a mixture of chloroform and ether chloroform with or without drug. The resulting two-phase system is then homogenized using homogenizer. The organic phase is removed under reduced pressure to form niosomes dispersed in aqueous phase. In some cases, resulting suspensions must be further hydrated or homogenized to yield niosomes.
Advantages of Niosomes
Structure of Niosomes
Types of niosomes
Methods of preparation of Niosomes
Ether injection method
Reverse phase evaporation
Micro fluidization 9
Two fluidized streams move forward through precisely defined micro channel and interact at ultra-high velocities within the interaction chamber. Here, a common gateway is arranged such that the energy supplied to the system remains within the area of niosomes formation. The result is a greater uniformity, smaller size and better reproducibility. 10 The mixture of cholesterol and diacetyl phosphate is prepared and solvent is then evaporated using rotary vacuum evaporator to leave a thin film. The film is then hydrated with aqueous drug solution and the suspension thus obtained is extruded through the polycarbonate membrane (mean pore size 0.1 nm) and then placed in series up to eight passages to obtain uniform size niosomes.
Extrusion method
2.6 Sonication method 10 The mixture of surfactant and cholesterol is dispersed primarily in the aqueous phase. This dispersion is then probe sonicated for 10 min at 60 °C, which leads to the formation of multilameller vesicles (MLV). These MLVs are further ultrasonicated either by probe sonicator or bath sonicator, which leads to the formation of unilameller vesicles. Water-cooled reflux and thermometer is positioned in the first and second neck and nitrogen supply through the third neck. Cholesterol and surfactant are dispersed together in this buffer (pH 7.4) at 70°C, the dispersion mixed for 15 seconds with high shear homogenizer and immediately afterwards "bubbled" at 70°C using nitrogen gas. 11, 12 The removal of unentrapped solute from the vesicles can be accomplished by various techniques, which include,
Separation of Unentrapped Drug
Dialysis:
The aqueous niosomal dispersion is dialyzed in dialysis tubing against phosphate buffer or normal saline or glucose solution.
Gel Filtration:
The unentrapped drug is detached by gel filtration of niosomal dispersion through a Sephadex-G-50 column and elution with phosphate buffered saline or normal saline.
Centrifugation
The niosomal suspension is centrifuged and the supernatant is separated. The pellet is washed and then resuspended to obtain a niosomal suspension free from unentrapped drug.
Evaluation of niosomes 4.1. Entrapment Efficiency
13
After preparing niosomes, unentrapped drug is separated by dialysis, centrifugation or gel filtration as described above and the drug remained entrapped in niosomes is determined by whole vesicle disruption using 0.1% Triton X-100 and analyzing the resultant solution by appropriate assay method for the drug .Where, Entrapment efficiency = Amount entrapped / Total amount used in preparation × 100.
Vesicle Diameter
13
Niosomes, similar to liposomes, assume spherical shape and so their diameter can be determined using light microscopy, photon correlation microscopy and freeze fracture electron microscopy.
Number of Lamellae
13
No of lamellae is determined by using nuclear magnetic resonance (NMR) spectroscopy, small angle X-ray scattering and electron microscopy.
Vesicle charge 14
The vesicle surface charge can participate an important role in the behavior of niosomes in vivo and in vitro. Generally, charged niosomes are more stable against aggregation and fusion than uncharged vesicles. In order to obtain an estimate of the surface potential, the zeta potential of individual niosomes can be measured by micro electrophoresis. An alternative approach is the use of pHsensitive fluorophores. More recently, dynamic light scattering have been used to measure the zeta potential of niosomes.
Bilayer Rigidity and Homogeneity
14
The biodistribution and biodegradation of niosomes are inclined by rigidity of the bilayer. In omogeneity can occur both within niosome structures themselves and between niosomes in dispersion and could be identified via. P-NMR, differential scanning calorimetry (DSC) and Fourier transform-infra red spectroscopy (FT-IR) techniques. Recently, fluorescence resonance energy.
Viscosity
15
Viscosity can be determined by using Ostwald viscometer. The niosomal formulation is poured in to the apparatus through the left arm up to the mark A. The formulation is was sucked in to the right arm slightly above the point B and the left arm is closed with the thumb to keep the liquid without dropping down. The apparatus is clamped vertically and then thumb is removed so as to allow the liquid to fall through the capillary under gravity then note down the time taken for the formulation to drop down from the point B to C. Then calculate the viscosity 14 by using poisulles equation as. ηl = ηw× tl× dl / tw × dw.
Stability studies
16
To carry out the stability of niosomes, the optimized batch is stored in airtight sealed vials at different temperatures. Surface characteristics and percentage drug retained in niosomes should be selected as parameters for evaluation of the stability, since instability of the formulation would reflect in drug leakage and a decrease. In the percentage drug retained. The niosomes were sample at regular intervals of time (0, 1, 2, and 3months), observed for color change, surface characteristics and tested for the percentage drug retained. 16 The simple method to determine in vitro release kinetics of the loaded drug is by incubating a known quantity of drug loaded niosomes in a buffer of suitable pH at 37 0 C with continuous stirring, withdrawing samples at some interval and analyzed the amount of drug by suitable analytical technique. Dialysis bags or dialysis membranes are commonly used to minimize interference. 17 TEM is used to determine the size, shape and lamellarity of niosome. In this a suspension is prepared and mixed with 1% phosphotungstic acid (in sufficient amount). A drop of resultant was then used on carbon coated grid, draining off the excess and then the grid was observed and images are taken under suitable magnification under TEM after complete drying (Philips TEM). 18, 19 1. Ophthalmic drug delivery A niosomal drug delivery system can be used for ophthalmic delivery. Cyclopentolate was encapsulated within niosomes prepared from polysorbate 20 and cholesterol and found to penetrate the cornea in a pH dependant manner within these niosomes. The increased absorption of cyclopentolate may be due to the altered permeability characteristics of the conjuctival and scleral membranes.
Transmission electron microscopy (TEM)
Applications of Niosomes
Diagnostic imaging with niosomes
Niosomes can be used as diagnostic agents. Conjugated niosomal formulation of gadobenate dimeglcemine with [N-palmitoylglucosamine (NPG)], PEG 4400, and both PEG and NPG exhibit significantly improved tumor targeting of an encapsulated paramagnetic agent assessed with MR imaging.
Niosomes as Drug Carriers
Niosomes are also used as carriers for iobitridol, a diagnostic agent used for Xray imaging. Topical niosomes may serve as solubilization matrix, as a local depot for sustained release of dermally active compounds, as penetration enhancers, or as rate-limiting membrane barrier for the modulation of systemic absorption of drugs.
Anti-neoplastic Treatment
Niosomes can alter the metabolism; prolong circulation and half life of the drug, thus decreasing the side effects of the drugs. Niosomes is decreased rate of proliferation of tumor and higher plasma levels accompanied by slower elimination.
Niosomes as carriers for Hemoglobin
Niosomes are also used as a carrier for hemoglobin. Niosomal suspensions show a visible spectrum super imposable on top of that of free hemoglobin. Vesicles are permeable to oxygen and hemoglobin dissociation curve can be modified similarly to non-encapsulated hemoglobin.
Leishmaniasis
Niosomes are also used to target drug in the treatment of diseases in which the infecting organism resides in the organ of reticuloendothelial system. Leishmaniasis is such a disease in which parasite invades cells of liver and spleen. The commonly prescribed drugs are antimonials, which are related to arsenic, and at high concentration they damage the heart, liver and kidney. Baillie et al reported increased sodium stibogluconate efficacy of niosomal formulation and that the effect of two doses given on successive days was additive.
Localized Drug Action
Drug delivery through niosomes is one of the important approach to achieve localized drug action, since their size and low penetrability through epithelium and connective tissue keeps the drug localized at the site of administration.
Conclusion
Niosomes are a structure similar to liposome and hence they can represent alternative vesicular systems with respect to liposomes, due to the niosome ability to encapsulate different type of drugs within their multienvironmental structure. Differrent methods are used for preparation of niosomes. Niosomes can be used for various purposes. It can be used as carrier for haemoglobin, targeting, localized action and all other.
